Loading…

Browse All Grants

20,252 grants found

Filters
Reset

Showing 2,0012,020 of 20,252 grants

Active NON-SBIR/STTR RPGS
Next-generation SMARTs for Discovery and Evaluation of Sequential Cancer Therapeutic Strategies
NATIONAL CANCER INSTITUTE Duke University United States 2023 – 2028

Treatment of cancer is an ongoing process during which clinicians make a series of decisions at critical points in a patient's disease by synthesizing baseline and evolving pa...

$3.7M
USD
Active NON-SBIR/STTR RPGS
Targeting cancer cachexia drivers using antibody-based approaches
NATIONAL CANCER INSTITUTE Virginia Commonwealth University United States 2023 – 2028

PROJECT SUMMARY Cancer-associated cachexia is a debilitated syndrome that has a dramatic impact on the quality of life and outcome of patients. Cancer cachexia occurs with a remark...

$4.11M
USD
Active NON-SBIR/STTR RPGS
Investigating the hnRNPA18-HIF-1a axis in solid tumors
NATIONAL CANCER INSTITUTE University of Maryland Baltimore United States 2023 – 2028

PROJECT SUMMARY Therapeutic approaches in cancer therapies have evolved from the use of highly toxic chemotherapy agents to precision medicine with well-defined targets and minimal...

$754.5K
USD
Active NON-SBIR/STTR RPGS
First in Class Small molecules to simultaneously inhibit protein translation and an immune checkpoint in cancers
NATIONAL CANCER INSTITUTE University of Maryland Baltimore United States 2023 – 2028

PROJECT SUMMARY Therapeutic approaches in cancer therapies have evolved from the use of highly toxic chemotherapy agents to precision medicine with well-defined targets and minimal...

$6.39M
USD
Active NON-SBIR/STTR RPGS
Development of novel AAV vaccine strategy in a pre-clinical model of oral melanoma.
NATIONAL CANCER INSTITUTE University of Minnesota United States 2023 – 2028

Project Summary/Abstract Vaccination is a potent regulator of the immune system and much research is being conducted to understand how antigen-specific stimulation can be used to i...

$5.04M
USD
Active NON-SBIR/STTR RPGS
Targeting Immune Escape in CML/MPN Transformation
NATIONAL CANCER INSTITUTE Beckman Research Institute/City of Hope United States 2023 – 2028

Myeloid neoplasms such as chronic myelogenous leukemia (CML) and myeloproliferative neoplasms (MPN) may over time transform from a chronic phase (CP) into, respectively, blast cris...

$5.72M
USD
Completed NON-SBIR/STTR RPGS
Quantitative evaluation of focused ultrasound thermal therapy on immunogenic cell death in breast cancer
NATIONAL CANCER INSTITUTE University of Utah United States 2023 – 2025

Triple negative breast cancer (TNBC) is resistant to conventional therapies, leading to poor disease-free survival and high recurrence rates. However, in contrast to other breast c...

$1.8M
USD
Active NON-SBIR/STTR RPGS
Targeting Protein Arginine Methyltransferases to Eradicate Acute Myeloid Leukemia
NATIONAL CANCER INSTITUTE Beckman Research Institute/City of Hope United States 2023 – 2028

Project Summary Treatment outcomes for patients with acute myeloid leukemia (AML) have continued to lag behind outcomes reported for other hematological malignancies like acute lym...

$7.27M
USD
Completed OTHER RESEARCH-RELATED
2023 SoCal Genome Stability Symposium
NATIONAL CANCER INSTITUTE University of Southern California United States 2023 – 2024

ABSTRACT The 2023 SoCal Genome Stability Symposium is a one-day conference that will be held at the University of Southern California, Los Angeles. The conference will focus on gen...

$70K
USD
Active NON-SBIR/STTR RPGS
Role of DeltaNp63 alpha and TIP60 in SCC progression and chemoresistance
NATIONAL CANCER INSTITUTE Wright State University United States 2023 – 2028

PROJECT SUMMARY / ABSTRACT Cisplatin is frequently used to treat squamous cell carcinoma (SCC), frequently in combination with other drugs or ionizing radiation (IR). Tumor recurre...

$6.51M
USD
Completed NON-SBIR/STTR RPGS
The mammary cell secretome as a novel biologic for triple-negative breast cancer
NATIONAL CANCER INSTITUTE Cornell University United States 2023 – 2025

SUMMARY Breast cancer accounts for nearly a quarter of all cancers in women and it remains the second leading cause of cancer deaths in the US, despite substantial changes in stand...

$1.83M
USD
Active NON-SBIR/STTR RPGS
Novel ctDNA biomarker for androgen therapy in metastatic prostate cancer
NATIONAL CANCER INSTITUTE Washington University United States 2023 – 2028

PROJECT SUMMARY The deadliest form of advanced-stage prostate cancer is treatment-resistant metastatic castration- resistant prostate cancer (mCRPC), which occurs in ~35% of patien...

$5.96M
USD
Active NON-SBIR/STTR RPGS
Causes and Consequences of Whole Genome Duplication in Cancer Progression and Acquired Drug Resistance
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2023 – 2028

Summary Recent studies show that whole genome duplication (WGD) is a frequent event in cancer evolution that promotes chromosomal instability and aneuploidy. WGD tumors have worse...

$4.78M
USD
Active NON-SBIR/STTR RPGS
Computational Feature Profiling and Modeling for Prostate Cancer Detection and Risk Stratification
NATIONAL CANCER INSTITUTE University of California Los Angeles United States 2023 – 2028

PROJECT SUMMARY/ABSTRACT Prostate cancer is the most common and second deadliest non-skin cancer in American men, accounting for 26% of new cancer diagnoses and 9% of cancer deaths...

$6.41M
USD
Completed NON-SBIR/STTR RPGS
Targeting FGFR4 to overcome chemoresistance in ovarian cancer
NATIONAL CANCER INSTITUTE University of Nebraska Medical Center United States 2023 – 2024

Abstract Many anti-tubulin agents, such as paclitaxel (Taxol), have been used extensively for treatment of several types of cancer, including ovarian, lung, and breast cancers. Des...

$2.15M
USD
Active NON-SBIR/STTR RPGS
Development of an Efficient 18F labeling technology based on tetrazine trans-cyclooctene ligation
NATIONAL CANCER INSTITUTE University of North Carolina Chapel Hill United States 2023 – 2027

Abstract: Proposed is the development of readily available tools for radiochemistry based on tetrazine ligation— a bioorthogonal reaction with rapid kinetics that has been studied...

$6.43M
USD
Completed NON-SBIR/STTR RPGS
Covalent PD1 Antagonists: Discovery of Protein-Protein Interaction (PPI) Inhibitors in Cancer Immunotherapy
NATIONAL CANCER INSTITUTE Florida Atlantic University United States 2023 – 2025

7. Project summary. Protein–protein interactions (PPIs) play a pivotal role in regulating a plethora of biological processes and their misregulations have been associated with a va...

$732.2K
USD
Completed NON-SBIR/STTR RPGS
Tetraacylated lipid A enhancement of checkpoint blocking cancer immunotherapy
NATIONAL CANCER INSTITUTE Harvard Medical School United States 2023 – 2025

PROJECT SUMMARY Immune checkpoint inhibitor (ICI) therapy is a therapeutic approach that blocks pathways that inhibit anti-tumor immunity and activates the immune system to fight c...

$2.38M
USD
Active TRAINING, INDIVIDUAL
Exploring the Impact of Genetic Ancestry on Acute Lymphoblastic Leukemia Risk in Latino Populations
NATIONAL CANCER INSTITUTE University of Southern California United States 2023 – 2027

PROJECT SUMMARY/ABSTRACT The overarching goal of this proposal is to employ and refine state-of-the-art gene discovery methods to uncover the genetic etiology of Acute Lymphoblasti...

$476.9K
USD
Completed TRAINING, INDIVIDUAL
Defining the mechanisms by which NuMA drives spindle mechanical robustness
NATIONAL CANCER INSTITUTE University of California, San Francisco United States 2023 – 2025

Project Summary/Abstract Errors in chromosome segregation lead to aneuploidy, a hallmark of cancer where daughter cells have extra or missing chromosome copies. Spindle pole defect...

$436.1K
USD